From: Validation of a derived version of the IPF-specific Saint George’s Respiratory Questionnaire
Characteristics | Value |
---|---|
Total cohort, n | 150 |
Male gender (%) | 122 (81.3%) |
Age, years (SD) | 72.9 ± 6.2 |
Smoking status | |
Never (%) | 40 (26.6%) |
Former (%) | 101 (67.3%) |
Current (%) | 9 (6.0%) |
FVC, % predicted (SD) | 87.2 ± 23.1 |
DLCO, % predicted (SD) | 48.4 ± 14.1 |
6MWD, m (SD) | 450.3 ± 112.5 |
Concurrent long-term oxygen therapy (%) | 19 (12.7%) |
Antifibrotic treatment, n (%) | 85 (56.7%) |
Pirfenidone, n (%) | 51 (34.0%) |
Nintedanib, n (%) | 34 (22.7%) |
Charlson comorbidity index (IQR) | 1 (0–2) |